Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BGB 15025

Next Previous
Drug Profile

BGB 15025

Alternative Names: BGB-15025

Latest Information Update: 23 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Hematopoietic progenitor kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 23 Oct 2023 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in China (PO) (NCT06029127)
  • 08 Sep 2023 BeiGene plans a phase II trial for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in China, Asia Pacific and worldwide (PO) in October 2023 (NCT06029127)
  • 05 May 2023 9388438- No updates
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top